ONTX Onconova Therapeutics Inc.

+0.1  (+3%)
Previous Close 3.68
Open 3.66
Price To Book 4.16
Market Cap 22293137
Shares 5,895,004
Volume 33,577
Short Ratio
Av. Daily Volume 89,098

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 Special Protocol Assessment (SPA) submission announced January 2, 2019.
Oral Rigosertib and azacitidine
First-line HR-MDS (high risk myelodysplastic syndromes)
Phase 3 enrolment to be completed 2H 2019.
IV Rigosertib - INSPIRE
2nd-line HR-MDS (high risk myelodysplastic syndromes)

Latest News

  1. Onconova Therapeutics to Present Update at the 2019 HCW Global Life Sciences Conference in London, April 7-9
  2. Edited Transcript of ONTX earnings conference call or presentation 26-Mar-19 1:00pm GMT
  3. Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2018 Financial Results
  4. Onconova Achieves Over 75 Percent of Planned Enrollment in Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes
  5. Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2018 Financial Results
  6. Onconova Therapeutics, Inc. to Participate at the 31st Annual ROTH Conference March 17-19, 2019 in Orange County, CA
  7. Onconova Therapeutics, Inc. to Present Corporate Update at the BIO CEO & Investor Conference in New York City
  8. Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City
  9. Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL
  10. Bucks County biopharm firm names new CEO
  11. Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer
  12. Onconova Submits Special Protocol Assessment (SPA) to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine (Vidaza®) for First-Line Myelodysplastic Syndromes (MDS)
  13. Onconova to Meet Investors and Potential Partners at China Focus and the 37th Annual J.P. Morgan Healthcare Conferences in San Francisco
  14. Onconova Welcomes Avi Oler, JD, MBA, as Vice President, Corporate Development and General Counsel
  15. Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting
  16. Edited Transcript of ONTX earnings conference call or presentation 13-Nov-18 2:00pm GMT
  17. Onconova Therapeutics Announces Business Highlights and Financial Results for Third Quarter 2018
  18. Onconova Welcomes Richard (Ric) Woodman, M.D., as Chief Medical Officer (CMO)
  19. Onconova Therapeutics (ONTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  20. Onconova Announces Four Presentations from Rigosertib Clinical Trials in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting & Exposition